Scientist profiles G-L
Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room G1 06
Administrative Assistant: Violet Izevbigie
Phone: 416-480-4055, ext. 7737
- MD, 1996, University of Toronto, Canada
- M.Sc., 2003, U of T, Canada
Appointments and Affiliations:
- Scientist, Evaluative Clinical Sciences, Trauma, Emergency & Critical Care Research Program, Sunnybrook Research Institute
- Lung health lead and scientist, Institute for Clinical Evaluative Sciences
- Research director and staff respirologist, Sunnybrook Health Sciences Centre
- Associate professor, department of medicine, U of T
- Associate professor, Institute of Health Policy, Management and Evaluation, U of T
- Adjunct scientist, The Hospital for Sick Children Research Institute
- Emerging Research Leaders Initiative Award, Heart and Stroke Foundation, Canadian Institutes of Health Research, Canadian Respiratory Research Network, 2016
- Assembly on Behavioral Science and Health Services Research Early Career Achievement Award, American Thoracic Society, 2015
- Early Researcher Award, Ontario Ministry of Research and Innovation and Ontario Ministry of Economic Development, 2015
- New Investigator Award, Canadian Institutes of Health Research, 2014
- Achievement, Commitment and Excellence Award, Ontario Ministry of Health and Long-Term Care, 2013
- Graham Farquharson Fellowship for Translational Health Research, Physicians’ Services Incorporated Foundation, 2013
- Respiratory disease
- Health services research
- Population-based studies
The focus of Dr. Gershon’s research is health outcomes, health services, quality of care and drug safety and effectiveness in people with respiratory disease.
See current publications list at PubMed.
- Gershon AS, Hwee J, Victor JC, Wilton D, Wu R, Day A, To T. Mortality trends in women and men with COPD in Ontario, Canada, 1996-2012. Thorax. 2015 Feb;70(2):121–6.
- Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R, Stephenson A, Stukel TA. Combination long-acting beta-agonists and inhaled corticosteroids versus long-acting beta-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014 Sep 17;312(11):1114–21.
- Gershon AS, Croxford R, Calzavara A, To T, Stanbrook M, Upshur R, Stukel T. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013 Jul 8;173(13):1175–85.
- Gershon AS, Guan J, Victor JC, Goldstein R, To T. Quantifying health services use for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013 Mar 15;187(6):596–601.
- Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet. 2011 Sep; 378(9795):991–96.
Related News and Stories:
- Clearing the air: Health services researcher probes treatment of understudied lung disease (Sept. 30, 2016)
- Treating C.O.P.D. in the elderly. (The New York Times, Oct. 13 2014)
- Bronchodilators have similar cardiovascular risks: study (Reuters Health, May 22, 2013)
- Similar cardiovascular risk observed with COPD drugs (Forbes.com, May 20, 2013)
- Asthma free for years, but not really cured (The Wall Street Journal, March 27, 2012)
- Study says there's no permanent relief from asthma (The Globe and Mail, March 8, 2012)
- Asthma likely to be a lifetime condition (CBC News, March 7, 2012)
- Lifetime risk for COPD higher than heart failure, common cancers (ABC News, Sept. 12, 2011)
- Study: 1 in 4 people likely to develop COPD (CBS News, Sept. 9, 2011)
- COPD lung disease 'huge burden' (CBC News, Sept. 9, 2011)
- Lifetime risk for COPD is one in four, study finds (CTV News, Sept. 8, 2011)